Vision Disorders (Hemeralopia)

Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peripheral vision. These may result from EYE DISEASES; OPTIC NERVE DISEASES; VISUAL PATHWAY diseases; OCCIPITAL LOBE diseases; OCULAR MOTILITY DISORDERS; and other conditions. Visual disability refers to inability of the individual to perform specific visual tasks, such as reading, writing, orientation, or traveling unaided. (From Newell, Ophthalmology: Principles and Concepts, 7th ed, p132)

Also Known As:

Networked: 178 relevant articles (16 outcomes, 8 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Edema
2.	Diplopia (Double Vision)
3.	Telangiectasis (Telangiectasia)
4.	Retinal Telangiectasis
5.	Macular Edema

Experts

1.	Okamoto, Fumiki: 4 articles (10/2015 - 05/2009)
2.	Oshika, Tetsuro: 4 articles (10/2015 - 05/2009)
3.	Okamoto, Yoshifumi: 4 articles (10/2015 - 05/2009)
4.	Hiraoka, Takahiro: 4 articles (10/2015 - 05/2009)
5.	Querques, Giuseppe: 3 articles (01/2013 - 07/2011)
6.	Souied, Eric H: 3 articles (01/2013 - 07/2011)
7.	Takada, Sonoko: 3 articles (02/2007 - 09/2003)
8.	Shimomura, Yoshikazu: 3 articles (02/2007 - 09/2003)
9.	Matsumoto, Chota: 3 articles (02/2007 - 09/2003)
10.	Hashimoto, Shigeki: 3 articles (02/2007 - 09/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Vision Disorders:

1.	Retinaldehyde (Retinal)IBA 09/01/2008 - "LE BCVA had improved to 20/25, metamorphopsias disappeared, and at OCT examination no retinal morphologic modification was evident. " 01/01/2006 - "Study of local visual activity, quantitative analysis of metamorphopsias, autofluorescence analysis of retinal pigment, and evoked visual multifocal potentials are regarded as innovations. " 02/01/1975 - "The present study demonstrates that the accommodative micropsia produced by a minus sphere lens is due to the retinal image minification introduced by the lens and to the change in convergence accompanying accommodation. " 12/01/2015 - "Recent theories suggest that both retinal and cortical mechanisms are involved in the development and changes of metamorphopsia. " 10/01/2015 - "The authors examined visual acuity, severity of metamorphopsia with M-CHARTS, and retinal microstructures with spectral domain optical coherence tomography before surgery and 3 months and 6 months after surgery. "
2.	ranibizumab (Lucentis)FDA Link 07/01/2011 - "The mean preferential hyperacuity perimeter metamorphopsia test score improved significantly from 20.4 ± 35 at baseline to 9.2 ± 23 after the single ranibizumab injection (p < 0.05). " 08/01/2011 - "Consecutive patients with newly diagnosed exudative AMD underwent the PHP metamorphopsia test, BCVA, and SD-OCT at five time points after initiation of ranibizumab therapy (0.05 mL/0.5 mg). " 07/01/2011 - "Fourteen consecutive patients with newly diagnosed choroidal neovascularisation underwent a preferential hyperacuity perimeter metamorphopsia test (main outcome measures) 1 h before (baseline) and 1 h, 1 day, 1 week and 1 month after one intravitreal injection of ranibizumab (0.05 ml/0.5 mg). " 04/01/2014 - "Patients completed a 3-month loading phase with monthly intravitreal injections of 0.5 mg ranibizumab, followed by a 12-month maintenance phase during which investigators documented VA, additional injections, metamorphopsias, routine ophthalmological examinations and adverse events at monthly follow-up visits. " 07/01/2011 - "The improvement in metamorphopsia test score after intravitreal ranibizumab injection, which correlated closely with improvement in several OCT parameters, suggests that the preferential hyperacuity perimeter test may be used to monitor the response to anti-vascular endothelial growth factor (VEGF) treatment in patients with exudative AMD."
3.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/01/2011 - "The improvement in metamorphopsia test score after intravitreal ranibizumab injection, which correlated closely with improvement in several OCT parameters, suggests that the preferential hyperacuity perimeter test may be used to monitor the response to anti-vascular endothelial growth factor (VEGF) treatment in patients with exudative AMD." 08/01/2011 - "Improvement in the metamorphopsia test score after intravitreal injections of ranibizumab, as well as its ability to predict the need for retreatment, suggest that PHP may be used to monitor response to anti-VEGF therapy in patients with exudative AMD."
4.	Fluorescein (Funduscein)FDA LinkGeneric 12/01/2010 - "Two patients presenting with visual loss and metamorphopsia were evaluated with fundal fluorescein angiography (FFA) and optical coherence tomography (OCT). " 05/01/2010 - "Best-corrected visual acuity, fundus examination, fluorescein angiography, optical coherence tomography, and the presence of metamorphopsia were assessed at baseline and then monthly. " 09/01/2006 - "The last patient had a residual tumour height of 1.2 mm, but no metamorphopsia, a normal foveal contour on OCT, and fluorescein angiography showed no residual leakage. " 04/01/1996 - "Therefore, if visual acuity decreases or metamorphopsia develops in these patients, careful biomicroscopic examination and fluorescein/ICG angiography is advisable." 12/01/1980 - "In some patients visual acuity and color perception were impaired and metamorphopsias were present, even though the macula appeared normal in funduscopy and fluorescein angiography. "
5.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/01/2014 - "In addition, they also suggest that, while statin and aspirin use may undoubtedly have some protective effects, they do not appear to be magic pills against the development of cognitive impairment or vision disorders in the elderly. " 01/01/2014 - "Cognitive Impairment and Age-Related Vision Disorders: Their Possible Relationship and the Evaluation of the Use of Aspirin and Statins in a 65 Years-and-Over Sardinian Population." 01/01/2014 - "Thus, the intent of the present study was to reliably establish whether a relationship exist between various types of dementia and age-related vision disorders, and to establish whether statins and aspirin may or may not have beneficial effects on these two types of disorders. " 01/01/2014 - "No significant association in statin use alone, aspirin use alone, or the combination of these was found in subjects without vision disorders but with dementia, and, similarly, none in subjects with vision disorders but without dementia. " 01/01/2014 - "When we considered the associations between different types of dementia and vision disorders and the use of statins and aspirin, we found a significant positive association between Alzheimer's disease and statins on their own or in combination with aspirin, indicating that these two drugs do not appear to reduce the risk of Alzheimer's disease or improve its clinical evolution and may, on the contrary, favor its development. "
6.	CellophaneIBA 01/01/2000 - "Postoperatively (26.5 months +/- 17.2) we found a cellophane maculopathy in 26.5% with consecutive metamorphopsia in 12.1%. " 01/01/2004 - "1. Vitrectomy with membrane peeling for preretinal macular membrane provides improvement in visual acuity and reduces metamorphopsia 2. Thin, cellophane-like appearance of the membrane gives a better prognosis of visual function improvement."
7.	ArgonIBA 10/01/1988 - "Obliteration of the neovascular membrane with confluent argon laser coagulation reduced metamorphopsia and prevented a progredient loss of visual acuity in all four patients." 04/01/1991 - "A 28-year-old man with unilateral Coats' disease and cystoid macular edema secondary to juxtafoveolar telangiectasis underwent successful juxtafoveolar argon green laser photocoagulation therapy with resolution of the edema and improvement in metamorphopsia and visual acuity. "
8.	verteporfin (Visudyne)FDA Link 05/01/2014 - "Half-dose verteporfin photodynamic therapy can be a therapeutic option for patients with good visual acuity who complain of metamorphopsia." 05/01/2014 - "The degree of metamorphopsia was measured with M-CHARTS before and at 1, 3, 6, 9, and 12 months after half-dose verteporfin photodynamic therapy. " 05/01/2014 - "Half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy results in significant improvements of metamorphopsia at 1 year, especially in eyes with good best-corrected visual acuity at the baseline. " 05/01/2014 - "To determine the degree of metamorphopsia before and 1 year after half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy. " 05/01/2014 - "Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy."
9.	Dopamine Agonists (Dopamine Agonist)IBA 06/01/2014 - "Because a dopamine agonist, a first-line therapy for moderate to severe RLS, caused the occurrence of metamorphopsia, an alternative treatment of gabapentin enacarbil was used; this treatment improved the patient's RLS without worsening her psychiatric symptoms. "
10.	SodiumIBA 04/01/2013 - "Visual acuity and retinal sensitivity were maintained, while metamorphopsia was improved 1 year after intravitreal pegaptanib sodium injections for myopic CNV."

Therapies and Procedures

1.	Vitrectomy 06/01/2000 - "Pars plana vitrectomy has been found to be effective in removing ERM from the macula, improving the visual acuity and decreasing metamorphopsia. " 02/01/2007 - "After vitrectomy, VA improved in 14 of 22 patients and metamorphopsia scores improved in 19 of 22 patients. " 05/01/2014 - "A surgical intervention using transconjunctival pars plana vitrectomy and membrane peeling is indicated depending on the reduction of visual acuity and the severity of metamorphopsia if present. " 01/01/2013 - "31 eyes from 31 consecutive patients with metamorphopsia and best corrected visual acuity (BCVA) below 20/32 underwent a transconjunctival 23- gauge vitrectomy with ERM and internal limiting membrane peeling. " 01/01/2002 - "In cases with no improvement of visual acuity after surgery, vitrectomy could reduce a metamorphopsia."
2.	Traction 01/01/2010 - "In conclusion, PEA orally administered, beyond a rare possibility of a spontaneous resolution of the vitreomacular traction, probably contributed, by anti inflammatory action, to the vitreolysis and thus to the disappearance of the vitreomacular traction and foveal hole with a subsequent recovery of the eyesight and of the metamorphopsia." 04/01/2009 - "Visual acuity increased by two Snellen lines, metamorphopsia disappeared, macular morphology was improved and myopic traction maculopathy was resolved. " 01/01/2014 - "A 78-year-old woman presented decreased visual acuity and metamorphopsia in the right eye due to vitreomacular traction. " 06/01/2010 - "New symptoms after the uploading phase with decreased VA or metamorphopsia may not necessarily relate to a progression of the AMD, but may also relate to a novel incomplete posterior vitreous vitreomacular traction possibly triggering the formation of traction and MH formation." 05/01/1999 - "Vitreoretinal surgery for syndromes with vitreomacular traction is indicated as it warrants a significant improvement of visual function and relief of metamorphopsia."
3.	Injections 08/01/2011 - "The mean PHP metamorphopsia test score improved from 25.6 ± 41 (baseline) to 10.7 ± 20.1 (P < 0.05) over 6 months, after a mean of 4.2 (±1.0) injections. " 04/01/2014 - "Patients completed a 3-month loading phase with monthly intravitreal injections of 0.5 mg ranibizumab, followed by a 12-month maintenance phase during which investigators documented VA, additional injections, metamorphopsias, routine ophthalmological examinations and adverse events at monthly follow-up visits. " 01/01/2013 - "This article is aimed to assess quantitatively metamorphopsia using M-charts in patients suffering from wet age-related macular degeneration (AMD) treated with the intravitreal bevacizumab injections and to compare the results with traditional Amsler grid and ocular coherence tomography (OCT). " 01/01/2013 - "M-charts as a tool for quantifying metamorphopsia in age-related macular degeneration treated with the bevacizumab injections." 04/01/2013 - "Visual acuity and retinal sensitivity were maintained, while metamorphopsia was improved 1 year after intravitreal pegaptanib sodium injections for myopic CNV."
4.	Lasers (Laser) 08/01/2007 - "Metamorphopsia was evaluated, with standard Amsler grids and a laser grid generated with a scanning laser ophthalmoscope (SLO). " 02/05/2004 - "[Laser correction for vision disorders is ever more popular. " 09/01/2003 - "The metamorphopsia scores were compared with the stages of ERM classified by scanning laser ophthalmoscope (SLO) images. " 05/01/2011 - "To compare, in eyes with an idiopathic epiretinal membrane (ERM), photoreceptor cell structural abnormalities identified on high-resolution images obtained by adaptive optics scanning laser ophthalmoscopy (AO-SLO) with the severity of metamorphopsia and anatomic findings on spectral-domain optical coherence tomography (SD-OCT). " 09/01/2009 - "This study identified early laser photocoagulation in central serous chorioretinopathy as an effective treatment regarding resorption of subretinal fluid, recovery of visual acuity, and improvement of metamorphopsia."
5.	Lenses 03/01/1976 - "reversible metamorphopsias by means of cylindrical lenses. " 03/01/1976 - "[The correction of labile metamorphopsias with cylindrical lenses (author's transl)]." 03/01/1996 - "The micropsia and diplopia were relieved by occlusion of one eye or by a base-out prism over one of the patient's eyeglass lenses. " 09/01/1976 - "Presbyopia was found to be the most prevalent vision disorder, and fifty-four per cent of the study population needed either prescription lenses for the first time or a significant change in their present spectacles for maximum visual acuity. " 04/01/1979 - "These lenses provide a means for treating amblyopia in schoolchildren and adults, as well as for eliminating diplopia, photophobia and metamorphopsia."